Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants

European Journal of Immunology
A R ThileniusJ H Russell

Abstract

We have produced three forms of human Fas: full-length Fas, Fas with a C-terminal deletion, and a chimera between extracellular Fas and the intracellular domain of the tumor necrosis factor receptor I p55 subunit. We transfected cell lines with these constructs to compare the relative capacity of antibody agonists and the physiological Fas ligand (FasL) to stimulate death. With two agonistic antibodies, the chimera is 100- to 1000-fold more sensitive to induction of death than the full-length Fas. The C-terminal deletion mutant also shows greatly enhanced death in comparison to the wild-type receptor. In contrast, when FasL is used to trigger the Fas pathway, wild-type Fas and the deletion mutant are similarly sensitive, whereas the chimera is 100-fold less susceptible to ligand-mediated killing than Fas. This demonstrates that antibody agonists and natural ligand can stimulate different signaling pathways and emphasizes the limitations of defining physiologically important signaling pathways solely by antibody agonists.

References

Sep 1, 1995·International Immunology·M HahneJ Tschopp
Oct 1, 1994·European Journal of Immunology·M GrellP Scheurich
Mar 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·M AdachiS Nagata
Oct 1, 1994·International Immunology·T TakahashiS Nagata
Sep 10, 1993·Cell·L A TartagliaD V Goeddel
Mar 1, 1996·The Journal of Biological Chemistry·A M ChinnaiyanV M Dixit

❮ Previous
Next ❯

Citations

Feb 14, 2004·Cellular Immunology·Rita N BárciaJulie D McLeod
Feb 23, 2000·Neuroscience·A M GormanS Ceccatelli
Mar 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M KawasakiN Hara
Dec 22, 1999·Journal of Viral Hepatitis·N Hayashi, E Mita
Sep 11, 2012·The Journal of Biological Chemistry·Fiona C KimberleyJan Paul Medema
Sep 10, 2013·Archives of Toxicology·Mathieu VinkenVera Rogiers
Dec 4, 2015·Toxicology and Applied Pharmacology·Michaël MaesHartmut Jaeschke
Apr 25, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·S ShenoyJ H Russell
May 27, 2004·The American Journal of Pathology·Morio NakamuraThomas R Martin
Oct 6, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·M L HyerJ S Norris
Mar 23, 1999·Nature Medicine·H J KaplanT A Ferguson
Aug 7, 2001·Reviews in Clinical and Experimental Hematology·E OrsiniR Foa
Aug 12, 2004·Xenotransplantation·Lijun BaiBernard E Tuch
Sep 16, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Caigan DuAnthony M Jevnikar
Aug 15, 2009·Cell Death and Differentiation·B Chaigne-DelalandeP Legembre
Nov 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J L WahlstenR R Caspi
Nov 25, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrick LegembreJean-Luc Taupin
Jan 16, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Samia Q KhanEckhard R Podack
Mar 23, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sixun Yang, Frank G Haluska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.